US imposes 2-year tariff exemption for generic drugs to incentivize domestic manufacturing

The US administration has granted a two-year tariff exemption for generic pharmaceuticals, contingent on companies transitioning production to domestic facilities. Failure to meet this deadline will trigger tariffs of up to 200%, marking a significant shift in supply chain policy for essential medicines.